Rockwell Medical

349 articles with Rockwell Medical

• Rockwell Medical Provides First Quarter 2022 Financial and Operational Update

  5/16/2022

  Rockwell Medical, Inc. reported financial results and a business update for the three months ended March 31, 2022.

• Rockwell Medical Submits Supplemental Data to FDA for IND Application for Phase 2 FPC Home Infusion Trial

  5/12/2022

  Rockwell Medical, Inc. (Nasdaq: RMTI), today announced that it provided the U.S. Food and Drug Administration (FDA) with the supplemental data, requested by the agency in December 2021, for the Company's pending Investigational New Drug (IND) application in support of a proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate (FPC).

• Rockwell Medical Announces 1-for-11 Reverse Stock Split

  5/12/2022

  Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, announced that its Board of Directors has approved a 1-for-11 reverse split of the Company's issued and outstanding common stock.

• Rockwell Medical, Inc. to Report First Quarter 2022 Financial and Operating Results on May 16, 2022

  5/11/2022

  Rockwell Medical , Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it will host a conference call on Monday, May 16 at 4:15 PM ET to discuss its financial results for the three months ended March 31, 2022, and recent operational highlights.

• 

  Clinical Catch-Up: Genentech Announces Positive Data, Pfizer Develops New Vaccine

  5/2/2022

  A roundup of last week's top clinical trial updates and news.

• Rockwell Medical Announces Completion of Patient Enrollment Ahead of Schedule in Pivotal Phase 3 Clinical Trial of Triferic® in China

  4/25/2022

  Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, today announced that its partner, Wanbang Biopharmaceuticals enrolled the final patient, ahead of schedule, in its pivotal Phase 3 clinical trial for Triferic® (ferric pyrophosphate citrate) Dialysate to support a new drug application for regulatory approval in China.

• Rockwell Medical to Present at Noblecon18 Investor Conference

  4/20/2022

  Rockwell Medical, Inc. today announced that the company is scheduled to present at the Noblecon18 , Noble Capital Market's 18th Annual Investor Conference in Hollywood, Florida, on Thursday, April 21st at 10:00 AM ET.

• Rockwell Medical Expands Partnership with DaVita

  4/11/2022

  Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, announced an expanded partnership with DaVita Inc., a leading kidney care provider.

• New Survey from Rockwell Medical Reveals Management of Iron Deficiency Anemia in Home Infusion Patients Does Not Adequately Address Medical Need

  3/15/2022

  Rockwell Medical, Inc. presented survey findings in oral and poster presentations at the National Home Infusion Association's 2022 Annual Conference, taking place March 12 through 16, 2022 in Nashville, Tennessee.

• Rockwell Medical Announces Upcoming Poster Presentation at the National Home Infusion Association’s 2022 Annual Conference

  3/9/2022

  Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced a poster presentation at the National Home Infusion Association’s (NHIA) 2022 Annual Conference.

• Rockwell Medical, Inc. to Present at Aegis Virtual Conference

  2/15/2022

  Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that the company is scheduled to present at Aegis Virtual Conference.

• Rockwell Medical Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Feb 14, 2022

  2/14/2022

  Rockwell Medical, Inc. announced that a majority of the independent directors serving on the Company’s Board of Directors approved an option grant to a new employee to purchase 10,000 shares of the Company’s common stock.

• Rockwell Medical Announces Regulatory Approval of Triferic® Dialysate in South KoreaTwo product forms of Triferic® are now approved in South Korea

  1/20/2022

  Rockwell Medical, Inc. (Nasdaq: RMTI) today announced that its partner in South Korea, Jeil Pharmaceutical Co., Ltd. (“Jeil”), has received a second regulatory approval by the Ministry of Food and Drug Safety of the Republic of Korea for Triferic® Dialysate (ferric pyrophosphate citrate sodium sulfate co-precipitate hydrate) for maintaining hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD).

• Rockwell Medical Announces Regulatory Approval of Triferic® AVNU in South Korea

  1/13/2022

  Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that its partner in South Korea, Jeil Pharmaceutical Co., Ltd. (“Jeil”), has received regulatory approval by the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea for Triferic Injection.

• Rockwell Medical, Inc. to Present at H.C. Wainwright BioConnect 2022 Conference

  1/7/2022

  Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced the Rockwell Medical executive management team is scheduled to present at the H.C. Wainwright BioConnect 2022 Conference.

• Rockwell Medical Receives Important Feedback from FDA on its IND Application for Phase 2 Trial of Ferric Pyrophosphate Citrate in Home Infusion

  12/14/2021

  Rockwell Medical, Inc. (Nasdaq: RMTI), today announced that it received feedback from the U.S. Food and Drug Administration (FDA) regarding its Investigational New Drug (IND) application in support of its proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate (FPC), designed for the treatment of iron deficiency anemia and maintenance of hemoglobin in patients receiving infusion therapy in the home setting.

• Rockwell Medical Study Demonstrates No Drug-drug Interaction Between Ferric Pyrophosphate Citrate and Unfractionated Heparin

  11/16/2021

  Rockwell Medical, Inc. announced the publication of results in the Journal of Bioequivalence & Bioavailability from a study designed to investigate the co-administration of intravenous Ferric Pyrophosphate Citrate with unfractionated heparin as an admixture via the HD-machine syringe pump.

• Rockwell Medical, Inc. Provides Third Quarter 2021 Financial and Operational Update

  11/15/2021

  Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, reported financial results and a business update for the three months ended September 30, 2021.

• Rockwell Medical Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Nov 12, 2021

  11/12/2021

  Rockwell Medical, Inc., a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, announced that a majority of the independent directors serving on the Company’s Board of Directors approved option grants to two new employees to purchase an aggregate of 75,000 shares of the Company’s common stock.

• Rockwell Medical Submits Investigational New Drug Application with FDA for its Proposed Clinical Trial of FPC as a Treatment for Iron Deficiency Anemia in Patients Receiving Home Infusion

  11/11/2021

  Rockwell Medical, Inc. today announced that it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in support of its proposed Phase 2 clinical trial of Ferric Pyrophosphate Citrate (FPC)